Ra Pharmaceuticals
Zilucoplan, a peptide complement C5 inhibitor for myasthenia gravis
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2008
- Latest Form D
- $29.2M, Jul 2015
- Total capital
- $39.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $39.6M
- 2 Form D · last Jul 2015
- 135 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 27
- 13 pending · first 2016
- Rank in peer group#64 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$29.2M
- Private capital raisedForm D · SEC · 1st filing$10.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#64 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Douglas A. TrecoExecutive Officer, DirectorNamed in SEC Form D filings
- Edward W. MathersDirectorNamed in SEC Form D filings
- James W. BroderickDirectorNamed in SEC Form D filings
- Jason A. LettmanDirectorNamed in SEC Form D filings
- Kerry A. BlackExecutive OfficerNamed in SEC Form D filings
- Lauren W. SilvermanDirectorNamed in SEC Form D filings
Show all 10 people
- Markus A. GoebelDirectorNamed in SEC Form D filings
- Peter A. BisgaardDirectorNamed in SEC Form D filings
- Rajeev A. ShahDirectorNamed in SEC Form D filings
- Theodore A. LaufikExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 27 granted of 40- PendingTreatment of Myasthenia Gravis with ZilucoplanUSPTOApplication 18862149
- GrantedModulators of Complement ActivityUSPTOUS 12,239,684
- GrantedModulation Of Complement ActivityUSPTOUS 11,965,040
Show all 40 patent records
- Treatment of Myasthenia Gravis with ZilucoplanSep 25, 2025 · Application 18862149Pending
- Modulators of Complement ActivityMar 4, 2025 · US 12,239,684Granted
- Modulation Of Complement ActivityApr 23, 2024 · US 11,965,040Granted
- Cyclic Polypeptides For PCSK9 InhibitionMar 19, 2024 · US 11,932,705Granted
- Cyclic Polypeptides For PCSK9 InhibitionNov 14, 2023 · US 11,814,445Granted
- Cyclic Polypeptides For PCSK9 InhibitionNov 14, 2023 · US 11,814,444Granted
- Modulators Of Complement ActivitySep 12, 2023 · US 11,752,190Granted
- Modulators Of Complement ActivityAug 15, 2023 · US 11,723,949Granted
- Modulators Of Complement ActivityJul 25, 2023 · US 11,707,503Granted
- Complement Modulators and Related MethodsApr 13, 2023 · Application 17442246Pending
- Modulation Of Complement ActivityDec 27, 2022 · US 11,535,650Granted
- Cyclic Polypeptides For PCSK9 InhibitionDec 20, 2022 · US 11,530,244Granted
- Neurological Disease Treatment With Complement InhibitorsNov 24, 2022 · Application 17642096Pending
- Cyclic Polypeptides For PCSK9 InhibitionNov 22, 2022 · US 11,505,575Granted
- Modulators Of Complement ActivityMay 26, 2022 · Application 17437082Pending
- Neurological Disease Treatment With ZilucoplanMay 5, 2022 · Application 17287581Pending
- Modulators Of Complement ActivitySep 21, 2021 · US 11,123,399Granted
- Modulation Of Complement ActivityMay 25, 2021 · US 11,014,965Granted
- Ras Binding Peptides And Methods Of UseMar 23, 2021 · US 10,954,287Granted
- Modulators Of Complement ActivityFeb 16, 2021 · US 10,918,691Granted
- Modulators Of Complement ActivityJan 7, 2021 · Application 16769732Pending
- Modulators Of Complement ActivityNov 17, 2020 · US 10,835,574Granted
- Formulations For Compound DeliverySep 10, 2020 · Application 16646263Pending
- Modulators Of Complement ActivityMar 17, 2020 · US 10,588,936Granted
- Modulation Of Complement ActivityFeb 18, 2020 · US 10,562,934Granted
- Modulation Of Complement ActivityOct 8, 2019 · US 10,435,438Granted
- Modulators Of Complement ActivityJun 25, 2019 · US 10,328,115Granted
- Peptide And Peptidomimetic InhibitorsApr 30, 2019 · US 10,272,132Granted
- Modulation Of Complement ActivityFeb 19, 2019 · US 10,208,089Granted
- Modulation Of Complement ActivityOct 23, 2018 · US 10,106,579Granted
- Peptide And Peptidomimetic InhibitorsJun 19, 2018 · US 9,999,650Granted
- Modulators Of Complement ActivityApr 10, 2018 · US 9,937,222Granted
- Peptide And Peptidomimetic InhibitorsMay 9, 2017 · US 9,644,004Granted
- Peptide And Peptidomimetic InhibitorsJan 19, 2016 · US 9,238,676Granted
- Neurological Disease Treatment With Complement InhibitorsApplication 62969742Pending
- Modulators Of Complement ActivityApplication 62976572Pending
- Inflammatory Disease Treatment With Complement InhibitorsApplication 62984827Pending
- Modulators Of Complement ActivityApplication PCTUS2020021330Pending
- Cyclic Polypeptides For PCSK9 InhibitionApplication PCTUS2019038250Pending
- Neurological Disease Treatment With Complement InhibitorsApplication 62988587Pending
Related companies, and why
- Mesentech Inc.Similar federal contract value in Biotech · null in contracts
- Aer TherapeuticsSimilar federal contract value in Biotech · null in contracts
- GRANATA BIO CorpSimilar federal contract value in Biotech · null in contracts
- Onconetix, Inc.Similar federal contract value in Biotech · null in contracts
- Culture Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- Pandion TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .